Background One‐third of patients with Crohn's disease (CD) or ulcerative colitis (UC)
receiving anti‐TNF s do not respond to treatment, and a relevant proportion experience loss …

Background Increased knowledge of pathways involved in the pathogenesis of IBD has led
to the development of new treatment options for Crohn's disease (CD) and ulcerative colitis …

Background Optimizing second-line biologic therapies for adult ulcerative colitis (UC) post
first-line failure is essential. Objective Compare second-line biologic therapy efficacy in adult …

Introduction: Anti TNF-α agents have become a significant advance in the management of
ulcerative colitis, proving to induce, with rapid onset, clinical and endoscopic remission …

The use of biologic agents, particularly anti-tumor necrosis factor (TNF)-α, has revolutionized
the treatment of inflammatory bowel diseases (IBD), modifying their natural history. Several …

Methods To construct this review article, we performed a systematic review of the literature to
identify relevant studies comparing anti-TNF monotherapy to combination therapy with an …

The management of moderate to severe ulcerative colitis has undergone significant
changes over the past 15 years due to the regulatory approval of several new drugs. In …

Background Golimumab efficacy data in ulcerative colitis (UC) are limited to anti–tumor
necrosis factor α (TNF)-naive patients. The aim of this study was to assess the short-term …

Many placebo controlled trials and meta-analyses evaluated the efficacy of different drugs
for the treatment of inflammatory bowel disease (IBD), including immunosuppressants and …

METHODS: A prospective observational study was conducted on patients with ulcerative
colitis, who started biological therapy with infliximab, adalimumab, golimumab, or …